BRAF-targeted therapy and immune responses to melanoma
BRAF-targeted therapy and immune responses to melanoma
复制标题
BRAF 靶向治疗和黑色素瘤的免疫反应
作者：
S. Ngiow;D. Knight;A. Ribas;G. McArthur;M. Smyth
I型BRAF抑制剂和免疫疗法构成了治疗晚期恶性黑色素瘤的两种令人兴奋的新方法。我们最近阐明了宿主C-C趋化因子受体2型（CCR 2）在小鼠中I型BRAF抑制剂的抑制作用中的作用，支持BRAF抑制剂与免疫疗法相结合的治疗潜力。
Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.
影响因子：
11.2
作者：
Koya RC;Mok S;Otte N;Blacketor KJ;Comin-Anduix B;Tumeh PC;Minasyan A;Graham NA;Graeber TG;Chodon T;Ribas A
通讯作者：
Ribas A
影响因子：
11.2
作者：
Boni, Andrea;Cogdill, Alexandria P.;Wargo, Jennifer A.
通讯作者：
Wargo, Jennifer A.